OraSure Technologies (OraSure Technologies) Cash-to-Debt : 21.51 (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is OraSure Technologies Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. OraSure Technologies's cash to debt ratio for the quarter that ended in Dec. 2023 was 21.51.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, OraSure Technologies could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for OraSure Technologies's Cash-to-Debt or its related term are showing as below:

OSUR' s Cash-to-Debt Range Over the Past 10 Years
Min: 8.84 Med: 5017.09 Max: No Debt
Current: 21.51

During the past 13 years, OraSure Technologies's highest Cash to Debt Ratio was No Debt. The lowest was 8.84. And the median was 5017.09.

OSUR's Cash-to-Debt is ranked better than
79.93% of 862 companies
in the Medical Devices & Instruments industry
Industry Median: 2.03 vs OSUR: 21.51

OraSure Technologies Cash-to-Debt Historical Data

The historical data trend for OraSure Technologies's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

OraSure Technologies Cash-to-Debt Chart

OraSure Technologies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

21.64

34.17

12.47

8.84

21.51

OraSure Technologies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															8.84	9.30	12.06	14.97	21.51

Competitive Comparison of OraSure Technologies's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, OraSure Technologies's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OraSure Technologies's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OraSure Technologies's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where OraSure Technologies's Cash-to-Debt falls into.

OraSure Technologies Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

OraSure Technologies's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	290.407	/	(2.116	+	11.388)
	=	21.51

OraSure Technologies's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	290.407	/	(2.116	+	11.388)
	=	21.51

OraSure Technologies (NAS:OSUR) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

OraSure Technologies Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of OraSure Technologies's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

OraSure Technologies (OraSure Technologies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OraSure Technologies Inc (NAS:OSUR) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

EP3:Germany

Address

220 East First Street, Bethlehem, PA, USA, 18015

Website

https://www.orasure.com

OraSure Technologies is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets most of its sales from the molecular solutions business, derived mainly from customers in the United States.

Executives

Kathleen Gallagher Weber	officer: Chief Product Officer	220 EAST FIRST STREET, BETHLEHEM PA 18017
Michele Marie Miller	officer: VP, Finance and Controller	220 EAST FIRST STREET, BETHLEHEM PA 18017
Robert W. Mcmahon	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kenneth J Mcgrath	officer: Chief Financial Officer	C/O ORASURE TECHNOLOGIES, INC., 220 E. FIRST STREET, BETHLEHEM PA 18015
Ronny B Lancaster	director	ORASURE TECHNOLOGIES INC, 220 EAST FIRST STREET, BETHLEHEM PA 18015
Mara G. Aspinall	director	7381 NORTH MOON SPIRIT LANE, TUCSON AZ 85718
Nancy J Gagliano	director	33 GRANITE WAY, GRANTHAM NH 03753
Michael Celano	director	220 EAST FIRST STREET, BETHLEHEM PA 18015
Manner Carrie Eglinton	director, officer: President & CEO	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Scott Gleason	officer: Interim CFO/SVP IR	1809 SOUTH 2500 EAST, SALT LAKE CITY UT 84108
Eamonn P Hobbs	director	C/O DELCATH SYSTEMS, INC., 600 FIFTH AVENUE, NEW YORK NY 10020
Anne Clem Whitaker	director	109 BRIERY BRANCH COURT, MORRISVILLE NC 27560
James A Datin	director	21 ESTATES DRIVE, DOYLESTOWN PA 18901
Lelio Marmora	director	64 RUE DE VESENEX, DIVONNE LES BAINS I0 01220
Lisa Nibauer	officer: President of Diagnostics	1 CRESENT PLACE, SHORT HILLS NJ 07078